Handelsbanken Fonder AB Purchases New Shares in Dianthus Therapeutics, Inc. $DNTH

Handelsbanken Fonder AB purchased a new position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) during the 2nd quarter, HoldingsChannel reports. The institutional investor purchased 15,300 shares of the company’s stock, valued at approximately $1,491,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in shares of Dianthus Therapeutics by 24.7% in the 4th quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock worth $84,417,000 after buying an additional 406,254 shares during the last quarter. UBS Group AG increased its position in shares of Dianthus Therapeutics by 342.6% during the fourth quarter. UBS Group AG now owns 606,620 shares of the company’s stock valued at $24,999,000 after acquiring an additional 469,547 shares during the last quarter. BNP Paribas Financial Markets increased its position in shares of Dianthus Therapeutics by 1,275.3% during the fourth quarter. BNP Paribas Financial Markets now owns 475,749 shares of the company’s stock valued at $19,606,000 after acquiring an additional 441,156 shares during the last quarter. SummitTX Capital L.P. lifted its holdings in Dianthus Therapeutics by 13.8% during the first quarter. SummitTX Capital L.P. now owns 100,044 shares of the company’s stock worth $8,396,000 after acquiring an additional 12,118 shares during the period. Finally, California State Teachers Retirement System lifted its holdings in Dianthus Therapeutics by 155.5% during the first quarter. California State Teachers Retirement System now owns 40,584 shares of the company’s stock worth $3,406,000 after acquiring an additional 24,697 shares during the period. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Insiders Place Their Bets

In other Dianthus Therapeutics news, Director Simon Read sold 2,777 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $109.55, for a total value of $304,220.35. Following the sale, the director directly owned 2,777 shares in the company, valued at $304,220.35. This represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Marino Garcia sold 166,000 shares of the firm’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $108.11, for a total transaction of $17,946,260.00. Following the completion of the transaction, the chief executive officer directly owned 65,292 shares of the company’s stock, valued at approximately $7,058,718.12. The trade was a 71.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 284,306 shares of company stock worth $29,289,369. Company insiders own 3.02% of the company’s stock.

Dianthus Therapeutics Stock Up 0.6%

Shares of DNTH opened at $115.54 on Wednesday. The business’s 50-day moving average price is $98.77 and its 200-day moving average price is $83.98. Dianthus Therapeutics, Inc. has a twelve month low of $20.69 and a twelve month high of $116.89. The stock has a market cap of $6.32 billion, a PE ratio of -27.84 and a beta of 1.22.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). The firm had revenue of $0.76 million during the quarter, compared to the consensus estimate of $0.30 million. Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. Analysts expect that Dianthus Therapeutics, Inc. will post -3.83 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. HC Wainwright boosted their price target on shares of Dianthus Therapeutics from $130.00 to $158.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $131.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday, August 5th. Truist Financial boosted their target price on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Friday, July 17th. Finally, TD Cowen restated a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $124.27.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.